Abstract Number: 0650 • ACR Convergence 2021
Use, Procurement Cost, and Adverse Events from IVIg Use in Rheumatic Disease
Background/Purpose: Intravenous immunoglobulin (IVIg) is used in several systemic rheumatic diseases due to postulated immunomodulatory properties. However, IVIg is a scarce and costly resource and…Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…Abstract Number: 1117 • ACR Convergence 2021
Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center
Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…Abstract Number: 1511 • ACR Convergence 2021
Investigation of Antigen Specific CD4+ T Cells in Patients with Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) also known as myositis, are rare chronic autoimmune disorders represented by lesions in muscle, skin and lung. One of the…Abstract Number: 1601 • ACR Convergence 2021
Satisfaction with Telemedicine in Immunosuppressed Children and Young Adults with Autoimmune Disease During the COVID 19 Pandemic: Are Their Needs Really Met? Preliminary Data from a Single Institution
Background/Purpose: COVID-19 can lead to severe and life-threatening complications, which is particularly unnerving for patients with autoimmune disease (AID) on immunosuppressive therapy. Telemedicine has enabled…Abstract Number: 1746 • ACR Convergence 2021
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…Abstract Number: 0098 • ACR Convergence 2021
Patients with Chronic Inflammatory Rheumatic Diseases Report a Lower Frequency of Infections Than Controls and They Protect Themselves Well Against SARS-CoV-2 Transmission
Background/Purpose: The SARS-CoV-2 pandemic has affected life in most countries around the world for more than a year now. It is not entirely clear if…Abstract Number: 0202 • ACR Convergence 2021
Variables Associated with Response to Therapy in Patients with Interstitial Pneumonia with Autoimmune Features
Background/Purpose: We have limited knowledge of the characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. Thus,…Abstract Number: 0444 • ACR Convergence 2021
COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey
Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…Abstract Number: 0651 • ACR Convergence 2021
Diagnostic Approach to Identifying Small Fiber Neuropathy in Patients with Sarcoidosis
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease that can affect the nervous system in about 5% of patients. Sarcoidosis associated small fiber neuropathy (SSFN) presents…Abstract Number: 0996 • ACR Convergence 2021
The Stimulator of Interferon Genes (STING) Protects from Bone Loss Through Regulation of Tonic and Induced Type I Interferon Pathways
Background/Purpose: The intracellular DNA sensing Stimulator of Interferon Genes (STING) pathway is critical for detection of viral and bacterial pathogen DNA. Hyperactivating mutations in this…Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…Abstract Number: 1516 • ACR Convergence 2021
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to…Abstract Number: 1602 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy in Rheumatology Outpatients in New York City
Background/Purpose: COVID-19 vaccination is particularly important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of infection with SARS-CoV-2 and of…Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
- « Previous Page
- 1
- …
- 56
- 57
- 58
- 59
- 60
- …
- 80
- Next Page »